Medicine and HealthNature Communications
Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy
Y. Li, Y. Cong, et al.
Exciting advancements in cancer therapy are on the horizon! This study by Ying Li and colleagues reveals that an innovative IL-21-anti-PD-1 antibody fusion protein significantly enhances memory T cell generation and boosts antitumor effects in mice, surpassing traditional PD-1 blockade methods. Discover how this could reshape immune checkpoint therapies!
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML
D. Nixdorf, M. Sponheimer, et al.
Medicine and Health
IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models
H. Shi, A. Li, et al.
Medicine and Health
TLR5 agonists enhance anti-tumor immunity and overcome resistance to immune checkpoint therapy
C. Gonzalez, S. Williamson, et al.
Medicine and Health
Locoregional delivery of IL-13Rx2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial
C. E. Brown, J. C. Hibbard, et al.
